Prediction: This Surprising Growth Stock Will Reach -- and Stay in -- the Trillion-Dollar Club in 2026.

Eli Lilly’s weight‑loss franchise—driven by tirzepatide products Mounjaro (T2D) and Zepbound (weight loss)—helped deliver a 54% revenue gain in the most recent quarter, and Goldman Sachs estimates the obesity/weight‑loss market could expand from roughly $28 billion today to about $95 billion by decade‑end (potentially >$100 billion thereafter). Lilly briefly touched a $1 trillion market cap last month and now sits near $904 billion; the firm is positioned to reclaim and potentially sustain a $1 trillion valuation in 2026 if current demand continues and if its oral GLP‑1 candidate orforglipron — notable for requiring no dietary restrictions and targeted for filing this year — commercializes successfully, although Novo Nordisk’s competing oral program and typical regulatory/commercialization risks will affect timing and upside.

Analysis

Eli Lilly's weight-loss franchise, led by tirzepatide sold as Mounjaro (T2D) and Zepbound (weight loss), underpinned a 54% revenue gain in the most recent quarter and helped the company briefly reach a $1 trillion market capitalization; the stock now sits near $904 billion. High demand for these products has been strong enough that both Lilly and Novo Nordisk have time on the FDA drug shortage list, demonstrating constrained supply amid rapid uptake.

Goldman Sachs Research estimates the obesity/weight-loss market is roughly $28 billion today and could expand to about $95 billion by decade-end and potentially surpass $100 billion thereafter, creating a sizable TAM that supports continued revenue expansion for market leaders. Lilly's oral GLP-1 candidate orforglipron — notable in the article for not requiring dietary restrictions — is slated for regulatory filing before year-end and, if approved and commercialized, would be an incremental growth driver versus current injectables.

Novo Nordisk has already applied for an oral candidate months earlier, so competitive timing is a key variable; regulatory review, commercialization execution and potential supply constraints are primary risks that could delay or temper upside. Sentiment signals are moderately positive overall with a strong per-ticker sentiment for LLY (0.7), implying market expectations are already partially priced toward continued weight-loss-led growth into 2026.

Key Decisions for Investors

• Consider accumulating or adding modest exposure to LLY ahead of the orforglipron filing while sizing positions conservatively given elevated valuation near $904 billion and regulatory execution risk
• Monitor regulatory milestones, early commercial uptake metrics and market-share data versus Novo Nordisk as primary catalysts that will determine whether 2026 re-rating to $1 trillion is sustainable
• If holding a concentrated position, employ option-based hedges or partial profit-taking to protect against approval delays, competitive surprises, or manufacturing/supply disruptions
• Reassess conviction if quarterly revenue growth meaningfully underperforms the recent 54% gain or if orforglipron faces a regulatory rejection or material label/launch restrictions